The high cost of PCSK9 inhibitors like Repatha
When the FOURIER trial was published in 2017, cardiologists and lipidologists everywhere hailed it as proof that lowering LDL with PCSK9 inhibitors “saves lives.” But when you actually read the data, not the press releases, it’s hard not to shake your head.
Over a median of 2.2 years, evolocumab (Repatha) reduced nonfatal heart attacks by about 0.9 percent and had no significant impact on death. The absolute risk reduction for all-cause …






![A neurosurgeon's fight with the state medical board [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-1-190x100.jpg)


![How one physician redesigned her practice to find joy in primary care again [PODCAST]](https://kevinmd.com/wp-content/uploads/The-Podcast-by-KevinMD-WideScreen-3000-px-3-190x100.jpg)

![Choosing the right doctor: How patients can take control of their care [PODCAST]](https://kevinmd.com/wp-content/uploads/Design-4-190x100.jpg)
